Oxford BioMedica plc · LSE:OXB

Oxford BioMedica — Merger or Acquisition (February 2018)

17 slides from Oxford BioMedica's merger presentation, Feb 15, 2018

  1. Slide 1: The LentiVector Platform Company

    The LentiVector® Platform Company A leader in gene and cell therapy Oxford BioMedica and Bioverativ Collaboration and Licence Agreement 15 February 2018

  2. Slide 2: Forward-looking statements

    Forward-looking statements This presentation does not constitute an offer to sell or a solicitation of offers to buy Ordinary Shares (the “Securities”). Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed 2 Cohort

  3. Slide 3: World's leading gene and cell therapy company

    World’s leading gene and cell therapy company Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Max. up to 30% Max. up to 50% Max. up to 44% Max. up to 30% 2, n=3 2x Original Mean 28% Mean 34% Mean 29%

  4. Slide 4: Strategy: Leveraging our delivery platform

    Strategy: Leveraging our delivery platform LentiVector® Platform IP – patents and know-how | Facilities | Expertise | Quality systems Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Max. up to 30% Max

  5. Slide 5: Collaboration & Licence Agreement

    Collaboration & Licence Agreement © Oxford BioMedica 2015, all rights reserved 5

  6. Slide 6: Collaboration & Licence Agreement with Bioverativ

    Collaboration & Licence Agreement with Collaboration overview Key Terms Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1,• n=3Development 1x of in vivo gene therapy for: Mean 27%• Original $5 million Mean 30%on closing Mean 29% Mean 20% Max. up to 30% Ma

  7. Slide 7: Bioverativ

    Bioverativ • Bioverativ was an independent biopharmaceutical company spun out of Biogen’s haemophilia business in 2017 but is now subject to an acquisition by Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) Sanofi 1, n=3 1x Original Mean 27% Mean 30% Mean

  8. Slide 8: Haemophilia Market

    Haemophilia Market • Haemophilia is an x-linked hereditary bleeding disorder characterised by impaired blood coagulation as result of deficiencies in the production or Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3function of 1x coagulation Factor

  9. Slide 9: How gene therapy addresses haemophilia

    How gene therapy addresses haemophilia In vivo gene therapy to produce FVIII and FIX to treat haemophilia A and B respectively Cohort2 Dose Administration 3 months (UPDRS) 1. DNA 6 months encoding (UPDRS) either FVIII 1 year (UPDRS) or(UPDRS) 2 years FIX 1, n=3 1x Original Mean 27% Mean is30%produce

  10. Slide 10: Oxford BioMedica's Latest Product Portfolio

    Oxford BioMedica’s Latest Product Portfolio © Oxford BioMedica 2015, all rights reserved 10

  11. Slide 11: Product pipeline

    Product pipeline Product Indication Pre-Clinical Phase I Phase I/II Phase II Phase III Approval OXB Proprietary Products OXB-102 Parkinson’s disease Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) OXB-202 Corneal graft rejection To be spun out 1, n=3 1x O

  12. Slide 12: Extensive lentiviral vector clinical/pre-clinical trial activity

    Extensive lentiviral vector clinical/pre-clinical trial activity New York Times, Gina Kolata Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year(27 (UPDRS) 2 years (UPDRS) November 2017) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Max. up to 30% Max. up to 50% "Few Max. u

  13. Slide 13: Summary

    Summary © Oxford BioMedica 2015, all rights reserved 13

  14. Slide 14: Summary: World's leading gene and cell therapy company

    Summary: World’s leading gene and cell therapy company Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Max. up to 30% Max. up to 50% Max. up to 44% Max. up to 30% 2, n=3 2x Original Mean 28% Mean 34%

  15. Slide 15: Expected upcoming news flow

    Expected upcoming news flow Partners’ programmes progress Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 2nd CAR-T Royalties Expected approval for Expected EMA approval for 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% programme to commence from

  16. Slide 16: Vision of Oxford BioMedica – by end of 2018

    Vision of Oxford BioMedica – by end of 2018 Core LentiVector® Product pipeline Bioprocessing platform R&D Bioprocessing Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) Facilities operating at, 1, n=3 product candidates New 1x OXB priority Original product

  17. Slide 17: Contact Us

    Contact Us Oxford BioMedica plc Windrush Court Transport Way Oxford OX4 6LT John Dawson, CEO Stuart Paynter, CFO Tel: +44 (0) 1865 783 000 [email protected] www.oxfordbiomedica.co.uk

Oxford BioMedica — Merger or Acquisition (February 2018) on 6ix